Loading...
COVID-19 and cancer: First report of the ESMO international, registry-based, cohort study (ESMO CoCARE)
Romano, E. Gennatas, S. Rogado, J. Sekacheva, M. Vinal, D. Lee, Rebecca J Croitoru, A. E. Vitorino, M. Khallaf, S. M. Susnjar, S.
Romano, E.
Gennatas, S.
Rogado, J.
Sekacheva, M.
Vinal, D.
Lee, Rebecca J
Croitoru, A. E.
Vitorino, M.
Khallaf, S. M.
Susnjar, S.
Citations
Altmetric:
Abstract
Background
At the height of the first wave of the SARS-COV-2 pandemic, ESMO mobilized to accelerate research for the understanding of COVID-19 in cancer patients (pts). ESMO CoCARE is an international collaborative registry-based, cohort study, gathering real-world data and information from healthcare professionals about the natural history, treatment and outcomes of COVID-19 in cancer pts.
Methods
ESMO CoCARE captures information on pts with any solid or hematologic malignancy (including cancer survivors free of disease for ?5 years) presenting with a COVID-19 diagnosis in any of the participating centers. Data collected since 06/2020 include demographics, cancer characteristics and status, co-morbidities, COVID-19 clinical features, course, management and outcome. Factors influencing COVID-19 severity (hospitalization +/- ICU support needed) and recovery are investigated using multivariable logistic regression with backward elimination method. The study is ongoing.
Results
The current analysis includes 1551 registered pts (19 countries; 87% pts from 23 European centers, 7% and 6% pts from 5 Northern African and 7 Asian centers), with COVID-19 diagnosis as of 11/03/2021. Median age was 64 years, with the majority female (52%), cancer stage III/IV (58%), and on active cancer treatment (60%). 65% had severe COVID-19 requiring hospitalization, with 11% receiving intensive care. In multivariable analysis, in addition to demographics (male gender, older age, other ethnicity than Caucasian, lower BMI), co-morbidities and symptomatic COVID-19, severe disease was associated to higher ECOG PS (Odds Ratio (OR)2 vs 0=5.9, OR1 vs 0=2.1), hematological malignancies (OR hemvs solid =2.0), and active/progressive cancer status (OR progressivevs no evidence of disease =1.6). 98% of pts with mild disease recovered, as opposed to only 70% of those with severe disease. Cancer stage was an additional prognostic factor for recovery (ORI/II vs IV =3.4).
Conclusions
Demographic characteristics, type and status of cancer, and symptomatology of COVID-19 increase the probability of severe disease, while advanced cancer stage is also associated with the risk of death.
Description
Date
2021
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 140.24 KB
Keywords
Type
Other
Citation
Romano E, Gennatas S, Rogado J, Sekacheva M, Vi�al D, Lee R, et al. 1567MO COVID-19 and cancer: First report of the ESMO international, registry-based, cohort study (ESMO CoCARE). Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S1133.